Table 5.

Competing regression analysis predicting cancer-specific mortality in patients with and without metastases.

	Without Metastasis at diagnosis				Metastasis at diagnosis
	HR	95% CI for HR		P	HR	95% CI for HR		P
		Lower	Higher			Lower	Higher
Age
≤60			reference				reference
>60 and ≤70	1.28	1.09	1.49	<0.001				0.862
>70 and ≤80	1.62	1.40	1.88	<0.001				0.286
>80	2.25	1.93	2.62	<0.001				0.311
Sex
Female							reference
Male				0.700	0.86	0.77	0.97	0.013
Race
White			reference				reference
Black				0.132				0.192
Other				0.749				0.628
Site
Ureter			reference				reference
Renal pelvis	0.90	0.82	0.99	0.029				0.188
Grade
Low level			reference				reference
High level	1.74	1.49	2.03	<0.001	1.29	1.01	1.66	0.044
Size
≤2 cm			reference				reference
>2 cm and ≤4 cm				0.618				0.433
>4 cm	1.38	1.20	1.58	<0.001				0.461
T
T1			reference				reference
T2	1.40	1.22	1.61	<0.001				0.167
T3	2.18	1.94	2.44	<0.001				0.433
T4	3.67	3.09	4.36	<0.001	1.43	1.17	1.75	<0.001
N
N0			reference				reference
N1	2.09	1.77	2.47	<0.001				0.190
N2	2.15	1.83	2.54	<0.001				0.195
N3	2.62	1.46	4.76	v				0.611
Surgery
None			reference				reference
Local tumor resection	0.43	0.36	0.52	<0.001	0.72	0.59	0.89	0.003
Nephroureterectomy	0.42	0.34	0.49	<0.001	0.64	0.53	0.76	<0.001
Lymphodissection
No			reference				reference
Yes	0.77	0.69	0.85	<0.001				0.632
Radiotherapy
No			reference				reference
Yes	1.39	1.16	1.67	<0.001				0.515
Chemotherapy
No			reference				reference
Yes				0.167	0.63	0.55	0.71	<0.001
Liver metastases
No							reference
Yes					1.23	1.05	1.45	0.014
Bone metastases
No							reference
Yes					1.35	1.15	1.58	<0.001
Brain metastases
No							reference
Yes					1.50	1.04	2.70	<0.001
Lung metastases
No							reference
Yes					1.18	1.02	1.37	0.025
Distant lymph node metastases
No							reference
Yes					0.80	0.66	0.96	0.019

HR, Hazard Ratio; CI, Confidence interval.